<DOC>
	<DOCNO>NCT01855100</DOCNO>
	<brief_summary>The objective NIS ass real-life setting , usage pattern associate outcomes management ( healthcare resource utilisation associate cost ) patient acute deep vein thrombosis treat Xarelto , accordance term European marketing authorization Belgian reimbursement criterion .</brief_summary>
	<brief_title>Belgian Real Life Non-interventional Study ( NIS ) Patients Treated With Xarelto Following Acute Deep Vein Thrombosis ( DVT )</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Adult patient diagnosis deep vein thrombosis ( DVT ) within past 9 month , enable least 3 month therapy Patients fulfil Belgian reimbursement criterion deep vein thrombosis ( DVT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Treatment acute deep vein thrombosis</keyword>
	<keyword>Prevention recurrence</keyword>
	<keyword>Oral anticoagulation</keyword>
	<keyword>Real-life setting</keyword>
</DOC>